سعر ايكاندرا بلس 50/1000مجم 30 قرص 2024

Vildagliptin 50 mg + metformin hydrochloride 1000 mg film-coated tablets, pack of 30 (3 strips), by Mash Premiere (Egypt); fixed-dose oral antidiabetic for type 2 diabetes.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled with metformin alone, already treated with vildagliptin and metformin as separate tablets, or in combination with other diabetes medicines including insulin when these do not provide adequate control.Population: AdultsEuropean Medicines Agency (EMA)

• Common adverse reactions include nausea, vomiting, diarrhoea, gastro-oesophageal reflux, flatulence, constipation, dizziness, headache, tremor and upper respiratory tract infection; decreased vitamin B12 absorption and lactic acidosis are very rare.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to the active substances or excipients; acute metabolic acidosis (lactic acidosis, diabetic ketoacidosis); diabetic pre-coma; severe renal failure (GFR below 30 ml/min); acute conditions that may alter renal function (dehydration, severe infection, shock, intravascular iodinated contrast); conditions causing tissue hypoxia (cardiac or respiratory failure, recent myocardial infarction, shock); hepatic impairment; acute alcohol intoxication or alcoholism; breast-feeding.International label, same formulation · European Medicines Agency (EMA)

• Lactic acidosis is a very rare but serious complication of metformin accumulation (acute worsening of renal function, cardiorespiratory illness, sepsis); temporarily stop in dehydration and seek medical attention immediately with symptoms such as acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia.International label, same formulation · European Medicines Agency (EMA)
• Stop metformin before or at the time of iodinated contrast imaging and at surgery under general, spinal or epidural anaesthesia; restart no earlier than 48 hours later once renal function is re-evaluated and stable.International label, same formulation · European Medicines Agency (EMA)
• Rare hepatic dysfunction (including hepatitis), acute pancreatitis and post-marketing bullous/exfoliative skin lesions have been reported with vildagliptin; discontinue if jaundice or confirmed pancreatitis occurs. Hypoglycaemia risk when combined with a sulphonylurea.International label, same formulation · European Medicines Agency (EMA)

• AlcoholAlcohol intoxication increases the risk of lactic acidosis with metformin (combination not recommended).European Medicines Agency (EMA)
• Iodinated contrast agentsStop metformin before or at the time of imaging; restart no earlier than 48 hours after, once renal function is stable.European Medicines Agency (EMA)
• NSAIDs, ACE inhibitors, angiotensin II receptor antagonists and diureticsMay impair renal function and increase lactic acidosis risk; close monitoring of renal function is needed.European Medicines Agency (EMA)

• There are no adequate data in pregnant women; the potential risk for humans is unknown and the combination should not be used during pregnancy.International label, same formulation · European Medicines Agency (EMA)
• Metformin is excreted in human milk in low amounts and vildagliptin data are lacking; because of the potential risk of neonatal hypoglycaemia, the combination should not be used during breast-feeding.International label, same formulation · European Medicines Agency (EMA)

• Vildagliptin: Selective DPP-4 inhibitor that increases endogenous GLP-1 and GIP.
• Metformin hydrochloride: